Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

5287 - Use of droplet digital polymerase chain reaction for detecting minimal residual disease: a prospective, multi-institutional study


28 Sep 2019


Poster Display session 1


Translational Research

Tumour Site


Hyunkyung Park


Annals of Oncology (2019) 30 (suppl_5): v435-v448. 10.1093/annonc/mdz251


H. Park1, D. Shin2, I. Kim2, S. Sohn3, Y. Koh2, J. Lee4, K. Lee4, D. Kim4, H. Kim5, J. Ahn5, J. Lee6, S. Bang6, J. Cheong7, S. Park8, S. Park9, Y.J. Lee10, S. Ahn5

Author affiliations

  • 1 Internal Medicine, Boramae Medical Center, 22332 - Seoul/KR
  • 2 Internal Medicine, Seoul National University Hospital, 03080 - Seoul/KR
  • 3 Internal Medicine, Kyungpook National University Hospital, 41944 - Daegu/KR
  • 4 Internal Medicine, Asan Medical Center, Seoul/KR
  • 5 Internal Medicine, Chonnam National University, Hwasun Hospital, Hwasun/KR
  • 6 Internal Medicine, Seoul National University, Bundang Hospital, Seongnam/KR
  • 7 Internal Medicine, Yonsei University, Severance Hospital, Seoul/KR
  • 8 Internal Medicine, Chosun University Hospital, Gwangju/KR
  • 9 Internal Medicine, Haeundae Paik Hospital, Busan/KR
  • 10 Internal Medicine, Kyungpook National University Hospital, Daegu/KR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5287


Droplet digital polymerase chain reaction (ddPCR) is an exact method of measurement in cancer research. The aim of this prospective study was to evaluate minimal residual disease (MRD) using ddPCR in patients with chronic myeloid leukemia (CML). We also evaluated treatment outcome depending on BCR/ABL1 transcript level using ddPCR.


Between May 2013 and November 2014, CML patients treated with nilotinib as the first-line therapy were enrolled. BCR/ABL1 transcripts levels were evaluated using ddPCR at the first time of complete molecular response (CMR). CMR was verified by quantitative real-time polymerase chain reaction.


We enrolled 15 patients from 7 institutions. The treatment period and median follow-up period were 45 months (range, 37–55 months) and 47 months (range, 39–61 months), respectively. The median value of BCR/ABL1 measured by ddPCR was 3.6 copies/20 μl (range, 1.2–6.8 copies/20 μl). Patients with a high level of BCR/ABL1 transcript had a greater tendency to lose the CMR during the follow-up period (0/10 (0%) for low levels vs. 2/5 (40%) for high levels, P = 0.095). In addition, patients with a low level of BCR/ABL1 transcript showed a longer duration of CMR than those with a high level (rate of sustained CMR at 2 years: 100% for low levels vs. 37.5% for high levels, P = 0.032).


We found that ddPCR is a sensitive method for detecting MRD and that MRD could affect the duration of the treatment response.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Novartis Pharmaceuticals Corporation.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.